Medindia

X

BioSpecifics Technologies Corp. to Present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference

Thursday, May 12, 2011 General News J E 4
Advertisement

LYNBROOK, N.Y., May 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference on Tuesday, May 17th at 9:30am EDT at the Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://noble.mediasite.com/mediasite/Viewer/?peid=546a50205ba1497a9a06f4122a1b3f071d.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX® in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Swedish Robotic-Assisted Surgical Program Grows, C...
S
PharmAthene Reports First Quarter 2011 Financial a...